What's Happening With Remdesivir?
Well, everyone was just dealing with the news that Gilead's antiviral remdesivir had had two trials suspended in China, when Stats Adam Feuerstein and Matthew Herper broke news last night about a trial here in the US.125 patients had been recruited at the University of Chicago to receive daily doses of remdesivir, and the only reason we have news of what's going on is because of a series of mistakes.